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IN a previous communication, Metcalf (1956) reported the presence of a
lymphocytosis stimulating factor in the plasma ofpatients suffering from chronic
lymphatic leukaemia. It was found that if such plasma was inoculated intra-
cerebrally into baby mice, a rise in the number of circulating lymphocytes was
produced in the peripheral blood. This effect reached its maximum intensity
after six days and passed off after fourteen days.
The inoculation of plasma from cases of acute lymphatic leukaemia, multiple
myeloma and acute and chronic myeloid leukaemia produced no effect on the
lymphocyte levels ofinoculated mice.
The effect was believed to have been produced either by a stimulation of
lymphocyte production or an induced prolongation of the life span of preformed
lymphocytes.
It is the purpose of the present paper to present the results obtained from an
examination of a wider range of haematological and other disorders. Lympho-
cytosis stimulating activity has been detected in the plasma of patients suffering
from two other disease states-lymphosarcoma and myelofibrosis.
It has been found that the plasma lymphocytosis stimulating activity (L S.A.)
diminishes following transfusions of whole blood and rises following the
intramuscular injection of adrenalin.
Concurrent administration of cortisone or oestrogens to inoculated mice
prevents the development of a subsequent lymphocytosis. The lymphocytosis
stimulating factor is heat-labile but withstands freeze-drying.
MATERIAL AND METHODS
Blood
Blood was obtained by sterile venepuncture. Ten ml. of blood were with-
drawn and placed in sterile heparinised bottles. This blood was centrifuged at
3000 r.p.m. for ten minutes and the supernatant plasma removed. This plasma
was either used immediately or stored at -15° C.
Mice
Mice used were those ofthe Hall Institute stock. This colony has been inbred
for many years, but is not genetically homozygous.
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The mice were inoculated when between 24 and 36 hours old. Care needs to
be taken in determining the age of the mice as the blood picture of baby mice
alters rapidly in the first week of life (Metcalf, 1956).
Following inoculation, the mice were returned to their mothers and left
untouched until blood counts were performed on them.
The number of mice in each litter was limited to a standard size of six per
nursing mouse. Provision of cotton wool nests for the mice was found useful in
minimising deaths from neglect immediately following inoculation.
Inoculation
The mice were inoculated intracerebrally with 0.01-0.02 ml. of plasma using
gauge 26 needles and graduated 0.25 ml. syringes.
Inoculations were made in a parasaggital plane midway between the ear and
the eye.
The mortality from inoculation was low. Excessive amounts of heparin in
the plasma were found to be rapidly lethal to mice of this age and an upper limit
of 100 units per 10 ml. of blood was found to be suitable.
Blood counts
Blood counts were performed at a fixed time in the day in all cases.
Blood was obtained from the mice on the sixth post-inoculation day by cutting
off the distal centimetre of the tail with a pair of sharp scissors. A free flow of
blood resulted from which blood films were made. These films were coded and
stained with Leishmann's stain.
Differential white cell counts were performed in the standard fashion and the
lymphocyte: polymorph ratio calculated.
In general twelve to eighteen mice were used for the estimation of L.S.A. in
each plasma sample. The mean of these estimations was taken as the L.S.A.
for that plasma sample.
Where absolute white cell counts were performed, tail blood was again used as
above, and counts were made in the standard manner using a modified Levy
haemocytometer.
Statistical Analysis
Analysis for statistically significant differences in the L.S.A. values of various
plasma samples was performed using the Student " t " series method for small
groups.
RESULTS
Preliminary considerations
It was previously noted (Metcalf, 1956) that the absolute lymphocyte count of
inoculated mice rose progressively following the inoculation of plasma showing
lymphocytosis stimulating activity (L.S.A.).
This effect was at its most constant, and reached its maximum, on the
sixth post-inoculation day. Serial daily blood counts are laborious and time-
consuming and do not permit the screening of large series of plasma samples or
detailed investigations on a particular plasma sample.
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It was, therefore, decided to restrict the measurement of L.S.A. to estimations
performed on the sixth post-inoculation day.
The lymphocyte: polymorph ratio as determined from differential white
counts on stained blood films proved a more reliable and consistent means of
estimating L.S.A., than the absolute lymphocyte count. This method of estima-
tion was adopted as the index of lymphocytosis stimulating activity (L.S.A.)
throughout the investigation.
Lymphocytosis stimulating activity in various diseases
It was established from a large series ofnormal plasma samples that the L.S.A.
of normal plasma varied between 10 and 3*1 with a mean figure of 2-5. This
range, in fact, represented the range of the lymphocyte: polymorph ratios of
normal uninoculated mice of this age.
It would seem, therefore, that the intracerebral inoculation of normal plasma
has no effect on the white cell levels in the peripheral blood-on the sixth post-
inoculation day at least.
In Table I are presented the results obtained from the screening for L.S.A. of
plasma samples from various types of leukaemia. In Table II are listed, in
abbreviated form, the results obtained from a survey of other disease states
involving the haemopoietic system.
It may be seenthat, ofthe various types ofplasma examined, only three disease
groups showed any lymphocytosis stimulating activity. These were: chronic
lymphatic leukaemia, lymphosarcoma and myelofibrosis.
All of the eighteen cases of chronic lymphatic leukaemia examined showed
lymphocytosis stimulating activity with the exception of one case (No. 2) in
TABLE I.-Lymphocyte/Polymorph Ratios on theSixth Day. Results using
Plasmafrom Various Types of Leukaemia
Chronic Chronic Acute Acute
Normal human lymphatic Lympho- Myelo- myeloid myeloid lymphatic Multiple
Patient. Normal mice. Plasma. Ieukaemia. sarcoma. fibrosis. leukaemia. leukaemia. leukaemia. myeloma.
1 4'2 3'9 4-7 2'3 2'6 3-1 2.3
2 *2.3 4.0 2.4 1-7 2.3 3.2 2*3
3 5-2 3.5 3.7 3.0 2.0 2*8 2.3
4 4-5 3-8 2.7 2-3 3.1 2.5 2.8
5 5-5 4.7 4.0 2-0 2*8 31 -
6 5.1 3.3 4.3 3-1 2-5 1 7 -
7 4.6 4.1 3'1 2.5 2.6 27 -
8 3.2 3-4 2.8 2.8 2.3 2.4 -
9 4.6 37 2- - 25 2'6
10 3-9 4.4 2'3 27 -
11 100Estimations100Estimations 4.3 3.7 - 28 - -
Range 1- 0-3 1 Range 1 0-3 1
12 4.4 3.2
- - 2*9 -
13 4-6 3-9 - - 27 - -
14 3.5 4-0 - - 28 -
15 4.9 3.3 - - 26 -
16 3.4 54
17 *30
-
18 41 -
Average
L/P ratios 2.5 2.6 4-2 3 9 3.5 2-5 2 6 27 2.4
Seetext.
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TABLE II.-Summary ofResults Obtained After Screening Various Diseases
showing Haematological Manifestations
No. of cases
showing plasma
Disease. No. of cases. L.S.A.
Glandular fever . . . . . . 16 . 0
WVhooping cough (> 30,000lymphocytes/cu. mm.). 4 . 0
Reticulum cell sarcoma . . . . . 3 . 0
Hodgkin's disease . . . . . . 4 . 0
Aplastic anaemia . . . . . . 4 . 0
Pernicious anaemia . 2 . 0
Tuberculosis ... 2 . 0
clinical remission and one case (No. 17) complicated by a secondary pyaemia
during the course of which, the patient's lymphocyte count fell from 55,000 to
5,000.
As described previously, (Metcalf, 1956) the actual level of L.S.A. observed
roughly paralleled the clinical activity of the disease at the time of examination.
Of sixteen cases of lymphosarcoma examined, all showed moderate levels of
L.S.A. Included in this group are two cases of follicular lymphoma. Three
cases of reticulum-cell sarcoma examined showed no L.S.A.
Of considearble interest was the unexpected finding of L.S.A. in the plasma of
five of eight cases of myelofibrosis examined. There have previously been no
clinical observations made relating myelofibrosis with the lymphatic leukaemia-
lymphosarcoma group of diseases, although the association of the disease with
myeloid leukaemia is well recognised. The possible relationship between this
plasma lymphocytosis stimulating factor and the hypothetical stem-cell stimulat-
ing factor in myelofibrosis will be discussed later.
It was realised that the groups of disease states showing plasma L.S.A. were
composed of patients who were middle aged and elderly, and as such, this age
range was not covered by the normal control group and the other disease groups.
Plasma samples from patients of this age group were, therefore, tested:
Included in this group were a number of cases of carcinoma of various sites.
The results obtained are shown in Table III. It may be seen that in no
instance was detectable L.S.A. found in the plasma samples.
In summary, it was found that lymphocytosis stimulating activity could be
detectedin the plasma ofsixteen ofeighteen cases ofchronic lymphatic leukaemia,
sixteen of sixteen cases oflymphosarcoma and five of eight cases ofmyelofibrosis.
In no other disease state examined was there detectablelymphocytosis stimulating
activity in the plasma.
Effect of Transfusion on Plasma L.S.A.
It has been estimated by Tivey (1954) that clinical remissions in acute
leukaemia occur in 20 per cent of cases following large or exchange transfusions.
Patients suffering from chronic lymphatic leukaemia are also often benefited by
whole blood transfusions.
Whitby (1951) has claimed that remissions may also be induced by transfusion
of fresh plasma and has postulated the presence of a factor in normal plasma
which, on administration, corrects a deficient or imbalanced state existing in
these patients.
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TABLE III.-Lymphocyte/Polymorph Ratios of Mice Inoculated with Plasma
from Middle-Aged and Elderly Patients with Various Diseases
L/P ratios of
No. of inoculated mice
estima- (normal range
Patient. Age. Disease. tions. 1.0-3.1).
CA . 60 . Cancer oflung . 6 . 2- 7
DO . 70 . Cancer ofoesophagus . 6 . 2
-3
SWA . 67 . Cancer ofstomach . 6 . 2
-6
RIG . 62 . Cancer oflung . 6 . 2-5
HOR . 72 . Cancer oflung . 6 . 2- 7
RO . 56 . Cancer oflung . 6 . 2 2
FRA 61 . Cancer ofstomach 6 . 2- 6
DAL . 64 . Cancer ofpancreas . 6 . 2-7
LIS . 68 . Coronary occlusion . 6 . 2-6
TAY . 62 . Chronic pancreatitis . 6 . 2-6
FOR . 53 . Cirrhosis ofliver . 6 . 2- 3
COL . 70 . Diabetes . 6 . 24
LIN . 58 . Rh.heartdisease . 6 . 2-8
WAL . 57 . Rh.heartdisease . 6 . 2-7
VIR . 69 . Coronary occlusion . 6 . 24
JO . 75 . Haematemesis . 6 . 2 6
It was of interest therefore, to determine the plasma L.S.A. of selected cases
before and after transfusions of whole blood.
For this purpose only previously untreated cases or cases in which other
therapeutic procedures had been suspended for some time were used in the
estimations. The group examined consisted of four cases of chronic lymphatic
leukaemia and two of lymphosarcoma.
The results obtained are shown in Fig. 1. Ofthe six cases examined, a definite
and immediate fall in plasma L.S.A. levels occurred following transfusion in four
of the cases. In remaining two cases there were also slight falls which did not
reach the level of significance. The volume of blood administered in each case is
indicated by the figures on the graphs. With the exception of the patient who
received one pint of blood by a direct transfusion, the source of blood was a
standard blood bank pool.
The depression in L.S.A. levels occurled promptly following transfusion and
appeared to persist for at least one to two weeks.
In five ofthe six cases, the clinical condition ofthe patients showed no improve-
ment other than that expected following the restoration of an adequate haemo-
globin level. The remaining case showed a return towards normal of W.B.C.
count, platelets and lymph node size. This improvement lasted for two months,
thereafter the patient's clinical condition deteriorated.
In an attempt to clarify the mechanism by which this depression of L.S.A.
levels was induced, the effect of in vitro addition of normal plasma to the pre-
transfusion active leukaemia plasma, was investigated. Equal volumes of
normal and leukaemic plasma were mixed at room temperature and allowed to
stand for one hour. The mixture was then inoculated into test mice. Inaddition,
serial dilutions in saline ofthe same active leukaemic plasma were made and tested
for detectable L.S.A.
The results are shown in Table IV.
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FIG. 1.-Plasma L.S.A. levels following transfusion offour cases ofchronic lymphatic leukaemia
and two cases oflymphosarcoma. Volume ofblood given indicated in pints.
TABLE IV.-Effect of dilution on plasma L.S.A.
Type of Plasma. Plasma L.S.A.
Pre-transfusion plasma . . . . . . 40
Plasma following transfusion offour pints ofblood (dilution ofpatient's
plasma = 1: 1.5) . . . . . . . . 2.4*
Pre-transfusion plasma + normal plasma (dilution of patient's plasma
= 1: 2) . . . . . . . .. 3 8
Saline dilutions ofpre-transfusion plasma, 1: 2 . . . . 3.5
1:5 . . . . 2.7*
1:10 . . . . 2.8*
* Significantly different from activity ofpre-transfusion plasma.
It may be seen from the table that the transfusion of four pints ofwhole blood
to the patient, producing at most a dilution of the patient's plasma of 1: 15, was
followed by a sharp fall in detectable L.S.A.
The in vitro dilution of the pre-transfusion plasma with normal plasma to a
dilution of 1: 2 produced no such effect.
Similarly, saline dilutions ofthe pre-transfusion plasma showed no diminution
in L.S.A. until a dilution of 1: 5 was reached.
It would seem unlikely, therefore, that the post-transfusion depression of
plasma L.S.A. is due simply to dilution ofthe patient's blood. The effect may be
dependent on secondary events occurring in the patient following transfusion.
Effect ofAdrenalin on Plasma L.S.A.
The elevation of blood lymphocyte levels following injections of adrenalin
is well known (Michael, 1949; White, Ling and Klein, 1950; Samuels, 1951).
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In the hope of demonstrating a similar effect on plasma L.S.A., selected
patients suffering from chronic lymphatic leukaemia were given intramuscular
injections of adrenalin and the plasma L.S.A. levels estimated.
Four patients were selected with moderately low plasma L.S.A. levels. They
were given intramuscular injection of 12 m. of 1/1000 adrenalin. Sterile
heparinised blood was collected at 5-minute intervals following the injection.
These samples were then tested for plasma L.S.A. in the usual manner.
Two of the patients developed haemolytic anaemia as a complication of their
leukaemic state These patients were subjected to splenectomy. The adrenalin
tests were repeated following splenectomy and again after the patients had been
placed on routine doses of cortisone (maintenance dose 75 mg. per day).
The results obtained are presented in Fig. 2.
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FIc. 2.-Plasma L.S.A. levels following intramuscular adrenalin: S +, with spleen intact.
S-, following splenectomy. C +, on cortisone therapy. C-, not on cortisone therapy.
It was found that a definite rise in plasma L S.A. followed the intramuscular
injection ofadrenalin. This rise did not run parallel with the transitory lympho-
cytosis exhibited by these patients. The lymphocytosis reached its maximum
and returned to normal levels within the first ten minutes. On the other hand,
as may be seen in Fig. 2, the plasma L.S.A. rose steadily throughout the observa-
tion period of 40 minutes.
The exact duration of the elevation of plasma L.S.A. was not determined,
but plasma L.S.A. levels hadreturned to thepre-injection levels when the patients
were retested a week after the test.
Splenectomy, in the two patients examined, appeared to have no influence
on the adrenalin-induced rise in plasma L.S.A.
However, when these patients were placed on cortisone therapy, and the
experiment repeated, no elevation of plasma L.S.A. occurred following the
adrenalin injections.
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It would appear, therefore, that adrenalin is capable of stimulating either the
production or release of L.S.A. This effect can occur in the absence of the spleen
andpresumably, therefore, the spleen, ifinvolved at all intheproduction ofL.S.A.,
is not the sole source of this factor.
Further, it seems that cortisone, in the doses used, is capable ofinhibiting this
production or release of excessive amounts of L.S.A. by adrenalin.
Effect of Cortisone and Oestrogen on the Lymphocytosis Response in the Mouse
In view of the known depressive effect of cortisone on blood lymphocyte
levels (Dougherty and White, 1947), the effect of the simultaneous
administration of active plasma and cortisone on the test mice, was investigated.
To check the effect of cortisone alone, day-old mice were injected
subcutaneously with 0-1 mg. of cortisone acetate daily for three days. When
examined at seven days of age, a significant fall in the blood lymphocytes was
found to have occurred.
Plasma of known activity was inoculated intracerebrally, simultaneously
with the first cortisone injections, and lymphocyte counts performed on the mice
six days later.
The mice did not show the customary lymphocytosis, the lymphocyte counts
were within normal limits, but were slightly higher than the counts on mice
treated with cortisone alone.
Table V shows the details of one such experiment.
TABLE V.-Effect of Cortisone on Plasma-Induced Lymphocytosis in Mice
Number of Mice
mice per Untreated Mice Mice + cortisone
Estimation. group. mice. + plasma. + cortisone. + plasma.
Average L/P ratio, normal range
1.0-31 . .. 18 . 2-5 . 4-4 . 1*2 . 1.7
Average total polymorphs/cu.
mm . . . . . 18 . 1000 . 800 1300 . 1500
Average total lymphocytes/cu.
mm . . 18 2500 3800 1600 . 2500
The significance of these results is not clear. They may represent the result
of a mutual antagonism between cortisone and the lymphocytosis stimulating
factor. A more likely interpretation is that the cortisone has, by a direct
destructive effect, depressed the level of circulating lymphocytes in both the
untreated mice and the mice showing a plasma-induced lymphocytosis.
The effect ofoestrogen on thelymphocyte levels ofnormal and plasma-treated
mice was next investigated.
Day-old mice were inoculated subcutaneously with 50 i.u. of oestroform
(oestradiol benzoate). No detectable effect on lymphocyte levels was observed
on the sixth post-injection day
When active plasma was inoculated simultaneously with the subcutaneous
oestroform, the expected lymphocytosis did not develop.
Table VI shows the results obtained.
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TABLE VI.-Effect ofOestrogen on Plasma-Induced Lymphocytosis
Number of
mice per Normal Mice Mice Mice + plasma
Experiment. group. mice. + plasma. + oestrogen. + oestrogen.
I . 10 . 2-7 . 3-8 . 29 . 2-4
II . 20 . 2.6 . 3-8 . 2-8 . 3-0
III . 20 . 2-6 . 4-1 . 2-8 . 2-2
It may be seen that whilst oestrogen alone had no significant effect on the
normal L/P ratio, it prevented the elevation of the L/P ratio following the
inoculation of active plasma.
Following on these results, a large group of mice of both sexes was inoculated
with a standard volume of active plasma. No observable difference in the level
of the lymphocytic response was found between the two sexes. This was not
surprising in view ofthe known sexual immaturity of mice ofthis age (cf. basis of
the Aschheim-Zondek test on considerably older mice).
Effect of heat andfreeze-drying on plasma L.S.A.
It was found that the lymphocytosis stimulating activity of active plasma
samples was lost following heating ofthe plasma to 60° C. for 15 minutes.
It was also found that the L.S.A. level of an active plasma sample withstood
storage at -15° C. for several months at least.
The activity of plasma samples was also found to withstand freeze-drying.
These results are listed in Table VII.
TABLE VII.-Effect of heat andfreeze-drying on plasma L.S.A.
Type ofplasma. L.S.A.
Plasma untreated . . . . . 3.8
Plasma heated to 60° C. for 15 minutes . . 2 5
2-5
2-7
Plasma stored at - 15° C. for 3 months . . 38
3-6
3-8
Plasma after freeze-drying . . . 3-7
3.9
DISCUSSION
The present work has confirmed the original finding that a high percentage of
patients, suffering from uncomplicated chronic lymphatic leukaemia, has present
in their plasma a factor capable ofstimulating a lymphocytosis in young mice.
In addition, two other disease states, lymphosarcoma and myelofibrosis,
appear to show similar plasma activity.
The finding of plasma L.S.A. in lymphosarcoma patients is in accord with
clinical and experimental experience that the disease is closely allied to, if not
identical with chronic lymphatic leukaemia.
There is no such obvious relationship between the two foregoing diseases and
myelofibrosis. It has been postulated by Dameshek (1951) and others that
myelofibrosis represents a disease in which the stem cells have been subjected to
continued and excessive stimulation. The effects of such stimulation may be
channelled either towards excessive activity of fibroblasts and osteoblasts or
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towards the eventual development of myeloid leukaemia. This stimulation may
be mediated by a circulating factor present in the plasma. Such plasma might
induce a lymphocytosis in an experimental animal whose only possible response
to stimulation ofits stem cells was alymphocytic one. Such a situation may exist
in baby mice, where it is known that, at this stage in their development, the
blood picture is undergoing conversion to a lymphocytic type.
At the present time, however, the detection of plasma L.S.A. in myelofibrosis
must remain an empirical observation.
The interpretation of the true biological function ofthe plasma lymphocytosis
stimulating factor in these disease states remains difficult.
The assumption, that the function of the factor in the human patient is
identical with the observed effect in mice, is to some extent supported by the
findings cfother workers using similar material in members oftwo other species-
guinea-pigs and human volunteers.
Foster and Miller (1950) reported a stimulation ofactivity in the lymph nodes,
and a variable lymphocytosis in guinea-pigs following intraperitoneal inoculation
of plasma from cases oflymphatic leukaemia.
Similarly, O]iva and Tramontana (1950) reported transient elevations of
circulating white celllevels following theintravenous infusion ofhuman volunteers
with leukaemic plasma.
It seems reasonable to assume, therefore, that the lymphocytosis stimulating
factor in the plasma ofthese patients may be involved either in the stimulation of
lymphocyte production or in the maintenance of elevated lymphocyte levels.
It was of interest that the plasma of patients with glandular fever and
whooping cough, who were exhibiting a lymphocytosis, showed no detectable
L.S.A. This was also found to be the case with plasma from cases of acute
lymphatic leukaemia. Thesepatients fallinto ayoung age group andit is possible
that the lymphocytosis stimulating factor may not appear in detectable amounts
in the plasma at this age.
Alternatively, the amount of circulating factor required to produce a given
level of lymphocytosis may be smaller in younger patients, and not detectable
by the present technique.
The possibility remains that the factor is a specific one and only produced in
certain disease states.
The effect of transfusions in lowering plasma L.S.A. is of interest. It may
represent a specific in vivo neutralisation of the lymphocytosis stimulating factor
by factors present in normal blood, but it is perhaps more likely to result from a
secondary in vivo reaction produced by the transfusion. Such a reaction may be
the release of excessive amounts of cortisone. In accord with this hypothesis is
the apparent antagonism by cortisone of the elevation ofplasma L.S.A. following
the intramuscular injection of adrenalin.
At this stage, neither the antagonistic effect of cortisone nor the stimulating
effect of adrenalin, on plasma L.S.A. levels, can be more than noted. Whether
the responses to these artificial stimuli represent normally occurring control
mechanisms of plasma L.S.A. levels in the body, is purely speculative.
Of similar significance is the finding of an apparent antagonism by oestrogens
of the L.S.A. effect. It is known that there is a sharp sex difference in the
incidence of the disease, males predominating. What relation there is between
these observations, can again only be speculated upon.
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In summary, the relation, between plasma L.S.A. and the disease states in
which it has been found to occur, may be:
(a) An unrelated phenomenon, at most representing a semi-specific by-
product of the disease state.
(b) A compensatory state by which normal lymphocytic activity is main-
tained following involvement of the body's normal complement of
lymphocytic tissue by disease.
(c) An aetiological relationship in which the continued presence of the
lymphocytosis stimulating factor leads to over-activity of the
patients lymphopoietic tissue with the final development of the
leukaemic or myelofibrotic state.
The potential use of the L.S.A. test as a diagnostic procedure is worthy of
consideration, but the value of such a test can only be assessed after a more
extensive screening of various disease states has been performed.
SUMMARY
1. A factor has been detected in the plasma of several disease states which is
capable of inducing a lymphocytosis in baby mice. These disease states are
chronic lymphatic leukaemia, lymphosarcoma and myelofibrosis.
2. The amount ofthe factor detectable in the patients' plasma is depressed by
transfusion of whole blood and during clinical remissions. It is elevated by the
intramuscular injection of adrenalin.
3. Both cortisone and oestrogens appear to suppress the lymphocytosis effect
of active plasma samples in mice.
4. Plasma activity is heat-labile but withstands freeze drying.
5. The significance of these findings is discussed.
I am indebted to Sir Macfarlane Burnet, F.R.S., for his advice and encourage-
ment throughout this work. I am also indebted to Dr. C. Stanton, Dr. B. M.
King and Dr. R. Hayesfortheir assistancewiththe clinicalaspects ofthisinvestiga-
tion, and to the Haematology Departments of the following hospitals for their
enthusiasm in providing blood samples and data: Royal Melbourne Hospital:
Alfred Hospital: Royal Children's Hospital: Cancer Institute: Fairfield
Infectious Diseases Hospital and St. Vincent's Hospital in Melbourne and Royal
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